1. Home
  2. NAGE vs IKT Comparison

NAGE vs IKT Comparison

Compare NAGE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Niagen Bioscience Inc.

NAGE

Niagen Bioscience Inc.

HOLD

Current Price

$3.49

Market Cap

261.2M

Sector

Health Care

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.23

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAGE
IKT
Founded
1999
2008
Country
United States
United States
Employees
117
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.2M
220.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NAGE
IKT
Price
$3.49
$2.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$16.00
$5.00
AVG Volume (30 Days)
719.7K
1.1M
Earning Date
05-06-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.51
N/A
Revenue Next Year
$14.58
N/A
P/E Ratio
$21.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$1.33
52 Week High
$11.29
$2.36

Technical Indicators

Market Signals
Indicator
NAGE
IKT
Relative Strength Index (RSI) 48.90 71.21
Support Level $3.35 $1.63
Resistance Level $3.60 $2.36
Average True Range (ATR) 0.16 0.16
MACD 0.02 0.02
Stochastic Oscillator 47.56 72.22

Price Performance

Historical Comparison
NAGE
IKT

About NAGE Niagen Bioscience Inc.

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: